Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145025 · ClinicalTrials.gov registry record
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- 3
- Enrollment target
NCT03145025: Completed study, sponsored by Bausch & Lomb Incorporated.
NCT03145025 is a clinical trial that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03145025 has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
Interventions
- DEVICE Retisert
- DRUG Fluocinolone Acetonide Intravitreal Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2019-03-22 |
What the finished NCT03145025 record still lists
NCT03145025 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Retisert is the first listed.
NCT03145025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03145025 about?
NCT03145025 is a clinical study titled "Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant". An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant
What is the current status of trial NCT03145025?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2017-07-14. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT03145025?
The interventions under investigation include: Retisert (DEVICE), Fluocinolone Acetonide Intravitreal Implant (DRUG).
Who is sponsoring clinical trial NCT03145025?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI